Statistical methods in gastroenterology & hepatology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Cochran-Mantel-Haenszel test
Risk difference
ANCOVA
Non-inferiority trial design
Multiple imputation / missing data
Odds ratio
Fisher exact test
Mixed-effects model
All gastroenterology & hepatology trials
642 results
- Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C: Complete Statistical AnalysisIndependent statistical analysis of Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02658019).
- Pembrolizumab (MK-3475) in Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (MK-3475) in Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02940496).
- Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PEPSIndependent statistical analysis of Prevention of Peritonitis in Peritoneal Dialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01293799).
- PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03685591).
- Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED): Complete Statistical AnalysisIndependent statistical analysis of Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED): primary endpoint results, effect estimate…
- Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pharmacokinetics of Omadacycline in Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Omadacycline in Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04460586).
- Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00711997).
- Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00588146).
- Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02047500).
- Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: primary endpoint results, effect estimate with confidence…
- Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03023722).
- Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05068752).
- Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas: Complete Statistical AnalysisIndependent statistical analysis of Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China: Complete Statistical AnalysisIndependent statistical analysis of Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- PHOTOIndependent statistical analysis of Pilot Trial of Phototherapy for Acute Depression in Hospitalized Cystic Fibrosis Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Physiological Flow of Liquids Used in Dysphagia Management (Neuro): Complete Statistical AnalysisIndependent statistical analysis of Physiological Flow of Liquids Used in Dysphagia Management (Neuro): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03192358).
- Physiology of GERD and Treatment Response: Complete Statistical AnalysisIndependent statistical analysis of Physiology of GERD and Treatment Response: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04292470).
- Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas: Complete Statistical AnalysisIndependent statistical analysis of Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PIOGASIndependent statistical analysis of Pioglitazone for Idiopathic Gastroparesis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04300127).
- Pioglitazone to Treat Fatty Liver in People With HIV Infection: Complete Statistical AnalysisIndependent statistical analysis of Pioglitazone to Treat Fatty Liver in People With HIV Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00441272).
- PlaceboIndependent statistical analysis of Efficacy of Open Label Placebo in Children With FGIDs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02389998).
- Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04177810).
- Ploidy and Stroma in Early Rectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ploidy and Stroma in Early Rectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03039595).
- PLUMIndependent statistical analysis of Post-Prandial Liver Glucose Metabolism in PCOS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03041129).
- POEMIndependent statistical analysis of Endoscopic Peroral Myotomy for Treatment of Achalasia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01405469).
- Polar Wand Carbon Dioxide Cryotherapy for Barrett’s Esophagus: Complete Statistical AnalysisIndependent statistical analysis of Polar Wand Carbon Dioxide Cryotherapy for Barrett's Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01477177).
- Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer: Complete Statistical AnalysisIndependent statistical analysis of Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00233389).
- POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).: Complete Statistical AnalysisIndependent statistical analysis of POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).:…
- Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pre-op Rectal ChemoRad +/- Cetuximab: Complete Statistical AnalysisIndependent statistical analysis of Pre-op Rectal ChemoRad +/- Cetuximab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00527111).
- Pre-operative Treatment for Patients With Untreated Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pre-operative Treatment for Patients With Untreated Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03138720).
- Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease: Complete Statistical AnalysisIndependent statistical analysis of Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03619811).
- Predictors of the Ability to Protect the Airway in Long-term Ventilated Patients: Complete Statistical AnalysisIndependent statistical analysis of Predictors of the Ability to Protect the Airway in Long-term Ventilated Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PREHABIndependent statistical analysis of A Supervised Prehabilitation Program for Patients With Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05692323).
- PrehabIndependent statistical analysis of Prehabilitation of Frail Surgical Cancer Patients Using Remote Ischemic Preconditioning: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03853473).
- Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01781403).
- PREPAREIndependent statistical analysis of PRevention Using EPA Against coloREctal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04216251).
- Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration: Complete Statistical AnalysisIndependent statistical analysis of Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Probability Ramp Control of Propofol for EGD: Complete Statistical AnalysisIndependent statistical analysis of Probability Ramp Control of Propofol for EGD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01838304).
- Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis: Complete Statistical AnalysisIndependent statistical analysis of Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size…
- Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses: Complete Statistical AnalysisIndependent statistical analysis of Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy: Complete Statistical AnalysisIndependent statistical analysis of Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…